Literature DB >> 21675881

Weighing the benefits of high-dose simvastatin against the risk of myopathy.

Amy Egan1, Eric Colman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21675881     DOI： 10.1056/NEJMp1106689

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

Review 1.  Initiation of statin therapy: are there age limits?

Authors:  Dipan A Desai; Sammy Zakaria; Pamela Ouyang
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

2.  Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.

Authors:  J S Schildcrout; J C Denny; E Bowton; W Gregg; J M Pulley; M A Basford; J D Cowan; H Xu; A H Ramirez; D C Crawford; M D Ritchie; J F Peterson; D R Masys; R A Wilke; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-06-27       Impact factor: 6.875

Review 3.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 4.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

Review 5.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

6.  Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power.

Authors:  Walter T Ambrosius; Tamar S Polonsky; Philip Greenland; David C Goff; Letitia H Perdue; Stephen P Fortmann; Karen L Margolis; Nicholas M Pajewski
Journal:  Clin Trials       Date:  2012-02-14       Impact factor: 2.486

7.  Use of administrative data to estimate the incidence of statin-related rhabdomyolysis.

Authors:  James S Floyd; Susan R Heckbert; Noel S Weiss; David S Carrell; Bruce M Psaty
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

8.  Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.

Authors:  Mostafa Shahrezaee; Ahmad Oryan; Farshid Bastami; Sepanta Hosseinpour; Mohammad Hossein Shahrezaee; Amir Kamali
Journal:  Endocrine       Date:  2018-01-25       Impact factor: 3.633

9.  New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.

Authors:  Taichi Ohshiro; Masaki Ohtawa; Tohru Nagamitsu; Daisuke Matsuda; Hiroaki Yagyu; Matthew A Davis; Lawrence L Rudel; Shun Ishibashi; Hiroshi Tomoda
Journal:  J Pharmacol Exp Ther       Date:  2015-09-03       Impact factor: 4.030

10.  Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Authors:  Marianne K DeGorter; Rommel G Tirona; Ute I Schwarz; Yun-Hee Choi; George K Dresser; Neville Suskin; Kathryn Myers; GuangYong Zou; Otito Iwuchukwu; Wei-Qi Wei; Russell A Wilke; Robert A Hegele; Richard B Kim
Journal:  Circ Cardiovasc Genet       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.